SEC Tracker
Get the app
GYRE · XBRL financial data

Gyre Therapeutics financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal years (GYRE's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Revenue from contracts with customers20,9487,338102,290113,450105,757116,588
Cost of goods and services sold——4,7934,6363,8845,416
Gross profit——97,497108,814101,873—
Research and development52,97568,889—13,78012,02413,698
General and administrative16,18018,96317,36614,66216,10920,804
Total operating expenses78,31895,2329,405176,04485,710105,101
Operating income (loss)(57,370)(87,894)(8,611)(67,230)16,16311,487
Other income (expense)659(87)—(1,518)(1,659)(1,505)
Income tax expense (benefit)——3488,5155,3204,556
Net income (loss)(56,241)(87,933)(8,242)(85,480)17,8989,880
Earnings per share, basic USD per share—(2.87)(0.26)(1.41)0.140.06
Earnings per share, diluted USD per share—(2.87)(0.26)(1.41)0.050.02
Weighted average shares, basic thousands of shares—30,64131,54665,83285,09589,345
Weighted average shares, diluted thousands of shares—30,64131,54665,832102,294103,180

Balance sheet

CSV

Fiscal years (GYRE's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Cash and cash equivalents30,36044,34721,66633,50911,81337,070
Short-term investments48,9942,504——14,85815,355
Marketable securities49,0002,5000———
Marketable securities, non-current2,500—————
Accounts receivable3,3131,818—15,16319,58931,078
Inventory——6,1224,2816,33710,171
Prepaid and other current assets6,8432,8071,540—2,6259,613
Total current assets89,51051,47628,20657,22164,786102,369
Property and equipment, net433970423,28823,88023,599
Right-of-use asset1,8322,744664891,8181,131
Total assets94,84655,66228,444116,539125,406166,132
Accounts payable5,9316,419194355108124
Total current liabilities17,79614,16516,82420,04719,51618,286
Lease liability, non-current981408121199885303
Total liabilities18,77714,57316,82438,06527,00423,850
Accumulated deficit(314,761)(402,694)(410,936)(85,538)(73,453)(68,426)
Total stockholders' equity76,06941,089(21,689)(15,828)63,319106,031
Total liabilities and equity94,84655,66228,444116,539125,406166,132
Common shares outstanding (cover page) thousands of shares31,33131,47737,76085,42393,61296,964

Cash flows

CSV

Fiscal years (GYRE's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Net income (loss)(56,241)(87,933)(8,242)(85,480)17,8989,880
Stock-based compensation3,6273,4051,3427,2818317,157
Depreciation and amortization1382902301,0741,5492,481
Net cash from operating activities(55,048)(83,755)(33,096)25,892(3,641)1,010
Purchases of property and equipment—8394,9858,5172,3151,190
Net cash from investing activities9,66348,18955,426(19,760)(19,884)(474)
Proceeds from issuing common stock————773—
Proceeds from issuing equity———2,500——
Dividends paid——45,031———
Net cash from financing activities60,37649,553(45,011)2,5002,10224,378
Net change in cash14,99113,987(22,681)8,334(21,696)25,257

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Gyre Therapeutics43,28729,105(16,728)*111.5M3.4 quarters 10-QJun 30, 2026
Volitionrx2,800399(5,160)*13.6M0.5 quarters 10-QJun 30, 2026
Oncolytics Biotech4,115not reported(8,138)*127.5M0.5 quarters 10-QJun 30, 2026
Seres Therapeutics17,528593not reported10.2M— 10-QSep 30, 2026
Macrogenics113,90732,832(40,748)*63.7M2.8 quarters 10-QJun 30, 2026
Inovio Pharmaceuticals31,5260(18,047)*103.4M2.0 quarters 10-QJun 30, 2026
XBiotech109,528not reported(4,515)*30.5M24.3 quarters 10-QJun 30, 2026
Oramed Pharmaceuticals15,245not reported(200)*41.6M80.5 quarters 10-QJun 30, 2026
Corbus Pharmaceuticals Holdings23,370not reported(29,626)*19.3M4.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.